Discover BiomX's Q2 2025 updates, including progress in phage therapy trials BX004 & BX211, financial highlights, and key insights into upcoming ...

Key Points GAAP EPS loss of $9.09 was narrower than the expected $9.24 per share for Q2 2025, a minor outperformance. Research and development expenses (GAAP) rose 29.2% to $2.2 million, reflecting ...

Research and development spending rose 14.3% compared to Q2 2024, reflecting a busy clinical pipeline, while the net loss (GAAP) increased to $10.4 million. These 10 stocks could mint the next wave of ...

Discover PDS Biotechnology's Q2 2025 progress on groundbreaking cancer trials, including VERSATILE-003. Explore durable outcomes and market growth potential.

Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license ...

Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients; Planning underway for potential registrational study Nature Communication ...

First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, ...

As the dust settles on its successful takeover of Awakn Life Sciences, investors are starting to appreciate the potential of ...

Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapies ...

Research and development expense (GAAP) rose approximately 65% year over year in Q2 2025 as clinical trials advanced. Net income (GAAP) shifted from $14.8 million in Q2 2024 to a net loss of $12.9 ...

Adolescence is a pivotal stage for sexual and reproductive health and rights (SRHR). Young adolescents (aged 10–14 years) ...

Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data ...